Format

Send to

Choose Destination
BMC Cancer. 2020 Feb 12;20(1):117. doi: 10.1186/s12885-020-6548-6.

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).

Author information

1
Gustave Roussy Cancer Campus, Villejuif, France. anna.patrikidou@sarahcannonresearch.co.uk.
2
Present Address: Sarah Cannon Research Institute and UCL Cancer Institute & University College London Hospitals, 93 Harley Street, London W1G 6AD, UK. anna.patrikidou@sarahcannonresearch.co.uk.
3
IRFC, Besançon, France.
4
Centre François Leclerc, Dijon, France.
5
Democritus University, Orestiada, Greece.
6
Gamma Knife Center, University of Minnesota, Minneapolis, MN, USA.
7
Centre Léon Bérard, Lyon, France.
8
Institut Claudius Regaud, Toulouse, France.
9
CHU Tours, Tours, France.
10
ICM, Montpellier, France.
11
CHU Clermont-Ferrand, Clermont-Ferrand, France.
12
Institut Paoli Calmettes, Marseille, France.
13
Centre René-Gauducheau, Nantes, France.
14
Institut Marie Curie, Paris, France.
15
Centre Oscar Lambret, Lille, France.
16
McGill University Health Centre, Montreal, Canada.
17
Centre Henri Becquerel, Rouen, France.
18
Hôpital La Timone, Marseille, France.
19
, Geneva, Switzerland.
20
Gustave Roussy Cancer Campus, Villejuif, France.

Abstract

BACKGROUND:

Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases.

METHODS:

We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index.

RESULTS:

The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a sub-group of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status.

CONCLUSIONS:

The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decision-making and outcomes research.

KEYWORDS:

Brain metastasis; Prognostic index; Sarcoma

PMID:
32050939
DOI:
10.1186/s12885-020-6548-6
Free full text

Supplemental Content

Full text links

Icon for BioMed Central
Loading ...
Support Center